Outpatient autologous stem cell transplantation in Royal Hobart Hospital, Tasmania: a single‐centre, retrospective review in the Australian setting

Several international centres have published their experiences with outpatient autologous stem cell transplantation (ASCT) as treatment of haematological malignancies.

[1]  I. Irving,et al.  A 14‐year retrospective analysis of indications and outcomes of autologous haemopoietic stem cell transplantation in regional Queensland: a single‐centre experience , 2020, Internal medicine journal.

[2]  D. Pilcher,et al.  The financial cost of intensive care in Australia: a multicentre registry study , 2019, The Medical journal of Australia.

[3]  M. Jädersten,et al.  The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 , 2019, Experimental Hematology & Oncology.

[4]  S. Parmar,et al.  Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma , 2017, European journal of haematology.

[5]  F. Morabito,et al.  Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity‐based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model , 2017, Clinical lymphoma, myeloma & leukemia.

[6]  A. Clemmons,et al.  Mixed outpatient–inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment , 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[7]  L. Koh,et al.  Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore , 2017, Bone Marrow Transplantation.

[8]  J. Friedberg,et al.  Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost‐effective , 2016, Cancer medicine.

[9]  J. Nates,et al.  Intensive care outcomes in adult hematopoietic stem cell transplantation patients. , 2016, World journal of clinical oncology.

[10]  D. Porter,et al.  Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma. , 2015, Clinical lymphoma, myeloma & leukemia.

[11]  D. Dingli,et al.  How we manage autologous stem cell transplantation for patients with multiple myeloma. , 2014, Blood.

[12]  H. Nakasone,et al.  Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. , 2014, The Journal of infection.

[13]  F. Ferrara,et al.  Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  O. Ballester,et al.  Frontline Therapy for Multiple Myeloma: A Concise Review of the Evidence Based on Randomized Clinical Trials , 2013, Cancer investigation.

[15]  G. Sauvageau,et al.  Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  B. Esterni,et al.  Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs , 2012, Bone Marrow Transplantation.

[17]  G. Morgan,et al.  Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). , 2011, Blood.

[18]  S. Lapinsky,et al.  Predictors of mortality in patients undergoing autologous hematopoietic cell transplantation admitted to the intensive care unit , 2009, Bone Marrow Transplantation.

[19]  H. Atkins,et al.  Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma , 2006, Annals of Hematology.

[20]  I. Kerridge,et al.  Hospital in the home (HITH) care following autologous stem cell transplantation for lymphoma and multiple myeloma. , 2006, The Australian journal of advanced nursing : a quarterly publication of the Royal Australian Nursing Federation.

[21]  N. Puig,et al.  Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation , 2006, Leukemia & lymphoma.

[22]  J. Cooney,et al.  Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma , 1999, Bone Marrow Transplantation.

[23]  R. Salazar,et al.  Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.

[24]  C. Huber,et al.  Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation , 1997, Bone Marrow Transplantation.

[25]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[26]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[27]  D C Linch,et al.  BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.